- CT1812 Treatment Showed ~40% Mean Improvement in Cognitive Measures vs Placebo -- Consistent Positive Changes Across Cognitive and Functional Measures -- Favorable Safety Profile with Most Treatment ...
PURCHASE, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results